Galectin Therapeutics Company Profile (NASDAQ:GALT)

About Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GALT
  • CUSIP: N/A
  • Web:
  • Market Cap: $75.95 million
  • Outstanding Shares: 34,670,000
Average Prices:
  • 50 Day Moving Avg: $2.41
  • 200 Day Moving Avg: $2.12
  • 52 Week Range: $0.49 - $3.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.77
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.02 per share
  • Price / Book: 115.30
  • EBIDTA: ($20,480,000.00)
  • Return on Equity: -546.35%
  • Return on Assets: -122.08%
  • Current Ratio: 3.21%
  • Quick Ratio: 3.21%
  • Average Volume: 186,737 shs.
  • Beta: 2.58
  • Short Ratio: 9.6

Frequently Asked Questions for Galectin Therapeutics (NASDAQ:GALT)

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) released its earnings results on Monday, May, 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01. View Galectin Therapeutics' Earnings History.

Where is Galectin Therapeutics' stock going? Where will Galectin Therapeutics' stock price be in 2017?

3 equities research analysts have issued 1 year price objectives for Galectin Therapeutics' stock. Their predictions range from $0.75 to $3.50. On average, they expect Galectin Therapeutics' stock price to reach $2.08 in the next year. View Analyst Ratings for Galectin Therapeutics.

Who are some of Galectin Therapeutics' key competitors?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:

  • Marc Rubin M.D., Chairman of the Board
  • Peter G. Traber M.D., President, Chief Executive Officer, Chief Medical Officer, Director
  • Jack W. Callicutt, Chief Financial Officer
  • Harold H. Shlevin M.D., Ph.D., Chief Operating Officer, Secretary
  • Eliezer Zomer Ph.D., Executive Vice President - Manufacturing and Product Development
  • J. Rex Horton, Executive Director - Regulatory Affairs and Quality Assurance
  • James C. Czirr, Director
  • Gilbert F. Amelio Ph.D., Independent Director
  • Kevin D. Freeman, Independent Director
  • Arthur R. Greenberg, Independent Director

Who owns Galectin Therapeutics stock?

Galectin Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include US Bancorp DE (0.34%). Company insiders that own Galectin Therapeutics stock include Arthur Greenberg, James C Czirr, Peter G Traber and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

How do I buy Galectin Therapeutics stock?

Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of Galectin Therapeutics stock can currently be purchased for approximately $2.19.

MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $2.08 (4.90% downside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/3/2017FBR & CoReiterated RatingMarket Perform$2.00MediumView Rating Details
3/30/2017HC WainwrightUpgradeNeutral -> Buy$3.50HighView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy -> Sell$3.00 -> $0.75N/AView Rating Details
8/12/2015MLV & Co.Reiterated RatingBuy$16.00N/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Galectin Therapeutics (NASDAQ:GALT)
Earnings by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Earnings History by Quarter for Galectin Therapeutics (NASDAQ GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.17)($0.13)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.22)($0.19)ViewN/AView Earnings Details
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
2017 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.15)($0.13)($0.14)
Q2 20172($0.16)($0.10)($0.13)
Q3 20172($0.12)($0.10)($0.11)
Q4 20172($0.10)($0.09)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Galectin Therapeutics (NASDAQ:GALT)
Insider Ownership Percentage: 40.30%
Institutional Ownership Percentage: 11.37%
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Institutional Ownership by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.00View SEC Filing  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Galectin Therapeutics (NASDAQ:GALT)
Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
DateHeadline logoGalectin Therapeutics Inc. (GALT) Downgraded by Zacks Investment Research - July 19 at 12:12 AM logoGalectin Therapeutics (NASDAQ:GALT) & Biohaven Pharmaceutical Holding Co (BHVN) Head-To-Head Comparison - July 18 at 2:45 PM logo Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.13 EPS - July 14 at 12:26 PM logoGalectin Therapeutics to Present at the Singular Research Summer Conference - GlobeNewswire (press release) - July 9 at 2:12 AM logoGalectin Therapeutics to Present at the Singular Research Summer Conference - July 8 at 10:57 AM logoAmmo, Inc. Appoints Two Senior Executives to Board of Directors - June 29 at 10:26 PM logoPatent for Reducing Inflammatory Response Granted to Galectin Therapeutics - GlobeNewswire (press release) - June 23 at 3:21 PM logo[$$] Drug Companies Seek to Raise Awareness of Liver Ailment - June 23 at 3:21 PM logoBRIEF-Galectin Therapeutics says patent granted for reducing inflammatory response - June 22 at 11:21 PM logoGalectin Therapeutics (GALT) Receives Patent for Reducing ... - - June 21 at 6:57 PM logoPatent for Reducing Inflammatory Response Granted to Galectin Therapeutics - June 21 at 6:57 PM logoGalectin Therapeutics Inc. (GALT) Expected to Post Earnings of -$0.13 Per Share - June 20 at 10:26 AM logoGalectin Therapeutics Inc. (GALT) Rating Increased to Buy at Zacks Investment Research - June 18 at 8:20 PM logoGalectin Therapeutics' (GALT) NASH CX Trial Should Continue, Says Independent Data Safety Monitoring Board - June 13 at 10:10 PM logoGalectin Therapeutics' (GALT) NASH CX Trial Should Continue ... - - June 13 at 5:10 PM logoBRIEF-Galectin Therapeutics updates on completion of Nash Cx trial - June 13 at 11:21 AM logoGalectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial - June 13 at 11:21 AM logoGeneric Drugs Stocks on Investors' Radar -- Catalyst Pharma, Lannett, Evoke Pharma, and Galectin Therapeutics - PR Newswire (press release) - June 7 at 11:06 AM logoAutoimmune Disease Patent Granted to Galectin Therapeutics ... - GlobeNewswire (press release) - June 6 at 10:46 PM logoBRIEF-Autoimmune disease patent granted to Galectin Therapeutics - June 6 at 5:45 PM logoAutoimmune Disease Patent Granted to Galectin Therapeutics - June 6 at 5:45 PM logoGalectin Therapeutics Inc (GALT) Short Interest Down 4.7% in May - June 4 at 9:46 AM logoGalectin Therapeutics Inc (GALT) Rating Lowered to Hold at Zacks Investment Research - May 26 at 10:28 PM logoGalectin Therapeutics: Serendipity In Psoriasis, Strength In NASH - Seeking Alpha - May 24 at 12:04 PM logoGalectin Therapeutics: 1 More Shot To Get It Right? - May 23 at 11:50 AM logoBRIEF-Galectin Therapeutics files for stock offering of up to $100 mln - May 19 at 10:10 PM logoGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update - Nasdaq - May 16 at 5:17 PM logoGalectin Therapeutics Inc (GALT) Posts Earnings Results, Misses Expectations By $0.03 EPS - May 16 at 5:10 PM logoGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update - GlobeNewswire (press release) - May 16 at 11:38 AM logo10-Q: GALECTIN THERAPEUTICS INC - May 15 at 11:24 AM logoGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update - May 15 at 11:24 AM logoGalectin Therapeutics (GALT) Receiving Positive News Coverage, Report Shows - May 4 at 10:10 AM logoGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease - May 3 at 5:09 PM logoZacks: Analysts Anticipate Galectin Therapeutics Inc (GALT) to Announce -$0.15 EPS - May 2 at 10:32 AM logoGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02 - Yahoo Finance - April 27 at 10:57 PM logoGalectin Therapeutics (GALT) Getting Positive News Coverage, Analysis Finds - April 26 at 6:00 PM logoGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02 - April 25 at 11:16 AM logoWill Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? - April 24 at 5:06 PM logoGalectin Therapeutics (GALT) Given Coverage Optimism Score of 0.56 - April 23 at 8:02 AM logoCan Mead Johnson (MJN) Spring a Surprise in Q1 Earnings? - April 20 at 12:12 PM logoGalectin Therapeutics (GALT) Earning Very Favorable Press Coverage, Report Finds - April 20 at 10:29 AM logoGalectin Therapeutics (GALT), Exalenz to Present Late-Breaking ... - - April 19 at 5:16 PM logoGalectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017 - April 18 at 11:32 AM logo5 Drug Stocks That Could Be Big Winners this Earnings Season - April 17 at 11:23 AM logoGalectin Therapeutics (GALT) Given Daily News Sentiment Rating of 0.10 - April 13 at 7:01 PM logoIntegra LifeSciences (IART) Q1 Earnings: A Beat in Store? - April 13 at 10:51 AM logoGalectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism - April 11 at 12:23 PM logo Brokerages Expect Galectin Therapeutics Inc (GALT) to Post -$0.15 EPS - April 10 at 10:22 PM logoGalectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7% - April 10 at 11:28 AM logoCan The Uptrend Continue for Galectin Therapeutics (GALT)? - April 7 at 9:57 AM



Galectin Therapeutics (GALT) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff